Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome.

Abstract

In November, 1999, all children under age 18 years in the UK were offered immunisation with the newly introduced meningococcal C conjugate vaccine (MCCV). In a cohort of 106 patients with nephrotic syndrome, there were 63 relapses during the 12 months before vaccination, and 96 during the equivalent period postvaccination (p=0.009). The relapse rate of nephrotic syndrome increased significantly after administration of MCCV. Whether to vaccinate such children needs to be carefully considered.

• Authors: A S Abeyagunawardena, D Goldblatt, N Andrews, R S Trompeter
• Journal: Lancet (London, England) (Lancet) Vol. 362 Issue 9382 Pg. 449-50 (Aug 09 2003) ISSN: 1474-547X [Electronic] England
• PMID: 12927434 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cytokines
• Meningococcal Vaccines
• serogroup C meningococcal conjugate vaccine

Topics

• Ambulatory Care
• Cytokines (adverse effects, immunology)
• Female
• Humans
• Male
• Meningitis, Meningococcal (immunology, prevention & control)
• Meningococcal Vaccines (adverse effects, therapeutic use)
• Nephrotic Syndrome (drug therapy, etiology, immunology)
• Recurrence
• Risk Factors
• Vaccination (adverse effects)